Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 24, 1997

View Archived Issues

Merck KGaA claims new Na+/H+-exchange inhibitors

Protein farnesyltransferase inhibitors prepared at Schering-Plough

Gedeon Richter discloses agents for neurodegenerative disorders

More new taxoids from Rhone-Poulenc Rorer

Study results of Crinone as ART treatment presented

Lilly presents structurally novel thrombin inhibitors

BioChem Therapeutic synthesizes antiangiogenic fumagillin analogues

MainGen Biotechnologie formation announced

Bristol-Myers Squibb and Genome Therapeutics sign database license agreement

FDA clears SKB's ReQuip

Micrologix Biotech and BCCA expand research for anticancer agents

p53 phase II trial for head and neck cancer

RenaGel safely and effectively binds phosphate in volunteers

Micro Therapeutics awarded patent for stroke treatment; reports preliminary clinical results

Duramycin available for licensing from MoliChem Medicines

Novel iron complex available for licensing from MoliChem Medicines

AEterna initiates phase I trial in AMD

VasoCare reduces stress in animal model of hypertension

Anti-IgE MAb progresses to late-stage clinical trials in asthma

Sparta receives SBIR grant from NINDS

Lisofylline collaboration expanded to include AML

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...